

The Future of TED

Active Clinical Trials in Thyroid Eye Disease

Several agents with new mechanisms of action are being investigated for the treatment of thyroid eye disease. Below is a list of agents with on-going clinical trials that are actively recruiting patients. Click the ClinicalTrials.gov link to find participating study sites near you.

Drug	Phase	Route of Administration	Dosing Frequency	ClinialTrials.gov
IGF-1R Inhibitors				
VRDN-001	Phase 3 (2 trials)	IV	Every 3 weeks	NCT05176639
			Every 3 weeks	NCT06021054
VRDN-003	Phase 3	SC	Every 4 or 8 weeks	Beginning in August 2024
Linsitinib	Phase 2b	PO	Twice daily	NCT05276063
AMG 732	Phase 1/2	SC	One dose	NCT06401044
Lonigutiamab	Phase 1/2	SC	Cohort 1: one dose Cohort 2: once weekly Cohort 3: every 4 weeks	NCT05683496
IL-6 Inhibitors				
Satralizumab	Phase 3 (2 trials)	SC	Every 4 weeks	NCT05987423
			Every 4 weeks	NCT06106828
TOUR006	Phase 2	SC	Every 8 weeks	NCT06088979
FcRn Inhibitors				
Batoclimab	Phase 2	SC	Once weekly	NCT05907668
	Phase 3		Once weekly	NCT05524571
Efgartigimod	Phase 3 (2 trials)	SC	Unknown	NCT06307626
				NCT06307613

FcRn, neonatal Fc receptor; IGF-1R, insulin-like growth factor 1 receptor; IL-6, interleukin-6; IV, intravenous; PO, by mouth; SC, subcutaneous